同步全身多参数2-[18F]FDG-PET/MRI在冒烟型多发性骨髓瘤评估中的诊断与预后价值
研究前瞻性纳入116例冒烟型多发性骨髓瘤(SMM)患者,评估全身多参数2-[18F]FDG-PET/MRI的诊断与预后价值。PET检出≥1个FL>5mm者占9%,MRI占20%(p=0.02);PET检出弥漫性骨髓受累者占20%,MRI占53%(p<10^-3)。98例真性SMM随访中,MRI弥漫性骨髓受累是PFS的最强不良预后因素(单因素HR 6.12;多因素HR 4.16,p=0.03),DCE-MRI的PEI和MITR升高亦为不良预后因素。
要点
- MRI对SMM骨髓弥漫性受累和FL的检出率均高于PET。
- MRI弥漫性骨髓受累是PFS最强不良预后因素(多因素HR 4.16)。
- DCE-MRI的PEI和MITR升高为其他强不良预后因素。
核心结论
- MRI弥漫性骨髓受累可被提议作为进展为症状性MM的新高风险生物标志物。
- DCE-MRI的PEI和MITR升高是其他强不良预后因素。
研究设计与样本
- 前瞻性研究纳入116例影像前无CRAB或SLiM标准的SMM患者,行全身多参数2-[18F]FDG-PET/MRI;98例真性SMM随访。
主要发现
- PET检出至少1个FL>5mm者占9%,MRI占20%(p=0.02)。
- PET检出弥漫性骨髓受累者占20%,MRI占53%(p<10^-3)。
- MRI弥漫性骨髓受累预测PFS的单因素HR为6.12(p<10^-2),多因素HR为4.16(p=0.03)。
- DCE-MRI的PEI和MITR升高为其他强不良预后因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The co-primary aims of this study were to assess the diagnostic and prognostic performance of Whole-body-2-[18F]-fluorodeoxyglucose-positron emission tomography coupled with MRI (WB-2-[18F]FDG-PET/MRI) imaging in the smoldering multiple myeloma (SMM) workup for detection of MM-related medullary or extra-medullary disease and for the prediction of progression-free survival (PFS) defined as time to progression to symptomatic MM requiring therapy. A total of 116 patients with SMM (without CRAB or SLiM criteria before imaging) were prospectively included in the study and underwent full multi-parametric WB-2-[18F]FDG-PET/MRI imaging. PET detected at least one FL > 5 mm in 9% of patients compared to 20% on MRI (p = 0.02). PET detected diffuse bone marrow involvement (BMI) in 20% of patients and MRI in 53% (p < 10-3). A total of 98 patients with true SMM not requiring treatment were then followed up. The presence of diffuse BMI on MRI was the strongest adverse prognostic parameter for PFS (univariate: hazard ratio (HR), 6.12; p < 10-2. Multivariate : HR, 4.16; p = 0.03) and could be proposed as a new high-risk biomarker for progression to symptomatic MM. Dynamic contrast-enhanced (DCE)-MRI based increased peak enhancement intensity (PEI) and maximum intensity time ratio (MITR) values were other strong adverse prognostic factors.
引用
- Jamet B, Touzeau C, Necib H, et al. Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact. Leukemia. 2025. PMID: 40775455. doi:10.1038/s41375-025-02717-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。